Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02267005
Recruitment Status : Completed
First Posted : October 17, 2014
Last Update Posted : May 11, 2018
Sponsor:
Information provided by (Responsible Party):
Brian Feldman, The Hospital for Sick Children

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This project will bring together a multidisciplinary team of pediatric rheumatologists, neurologists, metabolic geneticists and exercise physiologists to determine the effect of creatine (CR) supplementation on muscle function and muscle metabolism in children with Dermatomyositis (DM). The investigators propose using well-established exercise testing techniques as well as new, powerful exercise imaging protocols in order to better delineate the effects of CR on muscle pathophysiology in a non-invasive way. Evidence from this study will provide information regarding the effect of creatine supplementation on muscle function in DM. Improvements in muscle function and fatigue through CR use may also contribute to an improvement in quality of life and have significant clinical implications for the treatment of children with DM.

Condition or disease Intervention/treatment Phase
Juvenile Dermatomyositis Dietary Supplement: Creapure Dietary Supplement: Glucose Tablet Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis
Study Start Date : March 2015
Actual Primary Completion Date : May 2017
Actual Study Completion Date : May 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Myositis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Treatment
patients on this arm will be treated with creapure supplements
 Dietary Supplement: Creapure
Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
Other Name: ultrapure creatine monohydrate
Placebo Comparator: Placebo
patients on this arm will be given a placebo glucose tablet supplement
 Dietary Supplement: Glucose Tablet
Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
Other Name: Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Muscle function [ Time Frame: 6 months ]
    Will be determined by mean power output using a Wingate cycle ergometer protocol


Secondary Outcome Measures :
  1. Muscle metabolism [ Time Frame: 6 months ]
    The effects of creatine supplementation on key metabolites responsible for proper energy shuttling in healthy muscle will be measured at rest and using exercise protocols in subjects with P-MRS.

  2. Quality of life [ Time Frame: 6 months ]
    Both overall and health-related quality of life will be measured at each study visit with the Quality of My Life scale.

  3. Disease Activity [ Time Frame: 6 months ]
    Will be measured using the International Myositis Assessment and Clinical Studies Group (IMACS) before and after creatine supplementation

  4. Muscle Strength [ Time Frame: 6 months ]
    Will be estimated at each study visit from a maximal jump test and hand grip strength.

  5. Fatigue [ Time Frame: 6 months ]
    Will be determined using the PedsQL fatigue module which has been validated for use in children with fibromyalgia and rheumatic disease.

  6. Adherence [ Time Frame: 6 months ]
    This will be assessed based on a positive blood plasma and urine tests for creatine use over the course of the study period, amount of medication remaining and through self-reports using study diaries.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages 7 to 18 years
  • Diagnosis of probable JDM (onset <16 years) according to Bohan and Peter criteria
  • Subjects on a stable course of medication (unlikely to change over study treatment period as determined by the treating physician)
  • Minimum height of 132.5cm

Exclusion Criteria:

  • Subjects newly diagnosed with JDM within the previous 6 months
  • Subjects unable to cooperate with study procedures, or too weak to participate in the exercise testing
  • Subjects with impaired kidney function as determined from baseline visit screening lab values
  • Subjects who are currently pregnant or planning to become pregnant within the study period
  • Subjects who are shorter than 132.5cm
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02267005


Locations
Layout table for location information
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Sponsors and Collaborators
The Hospital for Sick Children
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Brian Feldman, Division Head, Rheumatology / Sr Scientist, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT02267005    
Other Study ID Numbers: 1000041466
First Posted: October 17, 2014    Key Record Dates
Last Update Posted: May 11, 2018
Last Verified: May 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatomyositis
Myositis
Polymyositis
Muscular Diseases
Musculoskeletal Diseases
 Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Skin Diseases